Delving into the Latest Updates on Jiangsu Kingsley Pharmaceutical Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Skin and Musculoskeletal Diseases

Respiratory Diseases

Interleukins

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Hemic and Lymphatic Diseases	2
Neoplasms	1
Infectious Diseases	1
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

HSA fusion protein	4
Interleukins	1
Fc fusion protein	1
Colony-stimulating factors	1

Top 5 Target	Count

IL-2R(Interleukin-2 receptor)	1
GLP-1R(Glucagon-like peptide 1 receptor)	1
EPO receptor(Erythropoietin receptor)	1
VEGFR(Vascular endothelial growth factor receptor)	1
IFNα2(Interferon alpha-2)	1

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 04 May 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

Preclinical

Phase 1

2

1

Phase 2

Approved

1

9

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Recombinant human interleukin-2(Jiangsu Kingsley Pharmaceutical Co Ltd) ( IL-2R )	Melanoma More	Approved
Albumin-erythropoietin fusion protein(Tianjin Puying Biotechnology Co Ltd) ( EPO receptor )	Anemia of renal disease More	Phase 1
rHSA-GLP-1 (FortuneRock Biotech) ( GLP-1R )	Diabetes Mellitus, Type 2 More	Preclinical
SFR-9X-012-2 ( VEGFR )	Corneal Injuries More	Discovery
rHSA/IL-2 (Fortunerock) ( IL-2 )	Eye Diseases More	Discontinued